Celldex Reported Co. Has Enough Money to Support Operations & Development. article here.
Motley Fool By: Jeremy Bowman March 7, 2013
Overall, the report looks strong with the company showing positive data from a phase 2b study of CDX-011 in metastatic breast cancer, as well as encouraging survival data from phase 2 studies of rindopepimut. The company's cash position also improved over 2012, adding $30 million through additional financing, which management said will "support operations and clinical development through 2015."